John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, explains the economics of antimicrobial development.
Interview Transcript (slightly modified for readability)
“I think it’s important to understand how the economics of antimicrobials work in the pharmaceutical industry. When a drug is studied, money is invested in order to develop that drug; when the drug is approved, then the drug is used and a return on that investment is realized by the company. The revenue, or sales, is a simple economic equation of the price which is charged [is multiplied] by the volume which is used. A model that rewards for a high-volume usage in the area of anti-infectives with a lower price is counter-intuitive to antimicrobial stewardship, because the more we use [them], the less effective they’re going to be.
We have to develop a model of a lower volume, and that may have to be offset by a higher price; however, we don’t expect the volume to be used high, [because] with a higher-priced drug you expect a lower volume; that will account for over-spending on these drugs.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512